GRAIL, Inc.
4 private offerings reported to the SEC on Form D since 2016, $2.2B sold in all. Biotech, California.
- Form D offerings: 4
- Reported sold: $2.2B
- Newest: Nov 7, 2025
- FDA records: Company page
Newest first; an amended notice updates the amount sold. Each filing opens on EDGAR.
| Nov 7, 2025 | — | $325.0M | $325.0M | GRAIL, Inc.Biotech · California | Not amended | 0001699031-25-000183 |
| Dec 12, 2019 | — | $388.4M | $425.0M | Grail, Inc.Biotech · California | May 7, 2020 | 0001699031-19-000002 |
| May 25, 2018 | — | $300.0M | Open-ended | Grail, Inc.Biotech · California | Not amended | 0000950103-18-006536 |
| Mar 14, 2017 | — | $1.2B | Open-ended | Grail, Inc.Biotech · California | Jan 11, 2018 | 0001699031-17-000001 |
- Ticker
- GRAL
- Business address
- Sunnyvale, Ca
- Incorporated in
- Delaware
- SEC industry
- Services-Medical Laboratories
- Former names
- Grail, LLC
- All SEC filings
- CIK 1699031 on EDGAR
- FDA records
- Approvals, clearances, recalls and letters
A Form D reports the amount offered and sold so far in a private offering, not who invested or at what valuation. Shares issued in a merger are left out. The profile is read from EDGAR daily. SEC Form D data sets and EDGAR